Top Markets
Coin of the day
Antisense Therapeutics Limited Antisense Therapeutics Limited

Antisense Therapeutics Limited

ANP
Rang in aandelen #33635
Antisense Therapeutics Limited, an Australian company headquartered in Toorak... Antisense Therapeutics Limited, an Australian company headquartered in Toorak and founded in 2000, specializes in the research and advancement of innovative antisense pharmaceutical drugs. Its primary pipeline asset, ATL1102, is an antisense inhibitor designed to target CD49d, which is currently in Phase II clinical trials for treating various inflammatory conditions such as multiple sclerosis, Duchenne Muscular Dystrophy, and asthma. Another promising therapeutic in their portfolio is ATL1103, a second-generation antisense drug that aims to block growth hormone receptor expression, thereby lowering insulin-like growth factor-I levels in the blood, and has completed Phase II clinical trials for conditions stemming from excessive growth hormone action.
Aandeelprijs
$0.03702159
Laatst gesynchroniseerd: 2024-01-29
Marktkapitalisatie
$7.21M
Verandering (1 dag)
-3.08%
Verandering (1 jaar)
0.00%
Land
AU
Handel Antisense Therapeutics Limited (ANP)

Categorie

Koersgeschiedenis voor Antisense Therapeutics Limited (ANP)
Hoogste slotkoers: $0.04 op 2024-01-01

Laagste slotkoers: $0.89 op 2001-12-01
Koersgeschiedenis van Antisense Therapeutics Limited van 2001 tot 2026
Jaarlijkse koersprestatie
Jaar Prestaties
2024 3.20%
2023 -37.05%
2022 -56.36%
2021 59.69%
2020 44.65%
2019 191.58%
2018 3.71%
2017 -27.93%
2016 -45.26%
2015 -30.97%
2014 -50.82%
2013 16.96%
2012 -52.56%
2011 252.85%
2010 -78.09%
2009 107.28%
2008 -31.61%
2007 18.43%
2006 15.79%
2005 -72.58%
2004 4.39%
2003 129.21%
2002 -69.82%
2001 0.00%
Aandelenkoers van vergelijkbare bedrijven of concurrenten
Bedrijf Aandelenkoers Verandering 1jr% Land
$171.67 -
DE
$161.32 22.99%
DE
$35.97 20.03%
JP
$225.71 37.95%
CH
$20.94 11.88%
IN